Company to Demonstrate How its Multiplo Rapid Tests can Maximize Impact, Efficiency and Return on Program Investments
HALIFAX, June 10, 2014 /CNW/ - MedMira Inc. (TSXV: MIR) will showcase its rapid HIV, hepatitis and syphilis multiplex test to more than 1,500 sexually transmitted disease (STD) and HIV experts this week at the 2014 STD Prevention Conference in Atlanta, GA. This biennial event, which concentrates on domestic and international STD prevention initiatives, gives community organizations, individuals, public health professionals, clinicians, and advocates the opportunity to exchange information about effective prevention. The theme for this year's conference is "More STD Prevention for the Money: Maximizing Impact, Efficiency and Return on Program Investments."
MedMira's Multiplo™ rapid diagnostics are built on the Company's patented Rapid Vertical Flow Technology™, which enables the simultaneously delivery of multiple tests results on a single test cartridge with one drop of specimen, saving healthcare providers and their patients time and money. These tests are extremely advantageous for diagnosing and treating populations at risk of multiple infections, such as HIV and hepatitis, which share similar transmission routes and impact treatment outcomes. They also benefit those whose access to care may be limited, and who may easily be lost to follow-up.
"Delivering multiple test results in a single visit is to everyone's advantage in STD prevention. Both the healthcare provider and the patients can benefit from reduced time and costs, and quicker access to the right course of treatment," said Neeraj Vats, Director of Technology and Business Affairs, MedMira Inc. "Our technology, and the multiplexing capabilities it delivers, creates opportunities for program managers and care providers to expand or combine existing testing programs dedicated to just one disease to encompass multiple diseases. They can triple the number of results they deliver without having to triple resources, testing time, and cost."
MedMira will present results illustrating that the performance of its rapid, easy-to-use screening/diagnostic tool, Multiplo Rapid HBc/HIV/HCV Antibody Test, is comparable to conventional laboratory methods for early detection of disease. The presentation will also outline how implementing multiplex tests in STD prevention programs can maximize return on investments
MedMira is currently implementing multicenter clinical trials for its Multiplo HBc/HIV/HCV test across the United States. MedMira's Reveal™ HBsAg rapid test, a new rapid test for hepatitis B surface antigen, and the Company's most advanced whole blood rapid HIV test, Reveal G4, are also part of these ongoing clinical trials. Moreover, MedMira's Multiplo TP/HIV test is currently advancing through the WHO prequalification of diagnostics process. Together, these tests give healthcare providers a powerful suite of rapid tools designed to better inform patients and maximize STD screening and diagnostic efforts.
MedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information:
Andrea Young, Corporate Communications
Chempetitive Group for MedMira: